



RECEIVED  
CENTRAL FAX CENTER  
OCT 30 2006

**AMENDMENTS TO CLAIMS**

1. (Withdrawn) Nucleic acids coding for polypeptides which exert the biological activity of an anti-Kazlauskas lipase and comprise an amino acid sequence according to SEQ ID NO: 2.
2. (Withdrawn) Nucleic acids according to Claim 1, characterized in that they are single-stranded or double-stranded deoxyribonucleic acids (DNA) or ribonucleic acids (RNA).
3. (Withdrawn) Nucleic acids according to Claim 1, characterized in that they are fragments of genomic DNA or cDNA.
4. (Withdrawn) Nucleic acids according to Claim 1, comprising a sequence selected from
  - a) the sequence according to SEQ ID NO: 1,
  - b) sequences coding for a polypeptide which comprises the amino acid sequence according to SEQ ID NO: 2,
  - c) partial sequences of at least 14 base pairs in length of the sequences defined in a) or b),
  - d) sequences hybridizing to the sequences defined in a) or b),
  - e) sequences which are at least 70% identical to the sequences defined in a),
  - f) sequences which are at least 70% identical to the sequences defined in b),

- g) sequences which are complementary to the sequences defined in a) or b),  
and
  - h) sequences which code for the same amino acid sequence as the  
sequences defined under a) to f), owing to the degeneracy of the genetic  
code.
- 5. (Withdrawn) DNA construct comprising a nucleic acid according to Claim 1 and a  
heterologous promoter.
  - 6. (Withdrawn) Vector comprising a nucleic acid according to Claim 1 or a DNA  
construct comprising said nucleic acid and a heterologous promoter.
  - 7. (Withdrawn) Host cell containing a nucleic acid according to Claim 1, a DNA  
construct comprising said nucleic acid and a heterologous promoter, or a vector  
comprising said nucleic acid or said DNA construct and a heterologous promoter.
  - 8. (Withdrawn) Host cell according to Claim 7, characterized in that it is a  
prokaryotic cell.
  - 9. (Withdrawn) Method for preparing a nucleic acid according to Claim 1,  
comprising
    - (i) chemically synthesizing the nucleic acid or
    - (ii)
      - a) chemically synthesizing oligonucleotides,
      - b) radiolabelling or labelling the oligonucleotides with a fluorescent  
dye,

- c) hybridizing the labelled oligonucleotides to DNA of a genomic or cDNA bank generated, starting from plant mRNA or genomic DNA,
    - d) selecting clones which the labelled oligonucleotides hybridize and
    - e) isolating the hybridized DNA, or
  - (iii) chemically synthesizing oligonucleotides and amplifying them by means of PCR.
10. (Withdrawn) Polypeptide having the biological activity of an anti-Kazlauskas lipase, which is encoded by a nucleic acid according to Claim 1.
11. (Withdrawn) Polypeptide having the biological activity of an anti-Kazlauskas lipase, which comprises an amino acid sequence which is at least 60% identical to an amino acid sequence according to SEQ ID NO: 2 across at least the section from amino acid 110 to amino acid 280.
12. (Withdrawn) Method for preparing a polypeptide according to Claim 10 characterized in that
- the preparation is carried out using **chemical methods** or
- host cells grown under conditions allowing expression of a nucleic acid, the grown host cells are harvested and the polypeptide is recovered therefrom and, where appropriate, purified.
13. (Currently Amended) A method Method for preparing a compound comprising a reaction according to the following equation X: ~~compounds of the formula (I)~~



where the formula (I) indicates the absolute configuration of the product, and in which

\* indicates a stereogenic carbon atom and

Ar is C<sub>6</sub>-C<sub>14</sub>-aryl and

R is cyano, C<sub>1</sub>-C<sub>12</sub>-alkyl, C<sub>1</sub>-C<sub>12</sub>-haloalkyl, C<sub>5</sub>-C<sub>11</sub>-arylalkyl or radicals of the formulae (IIa) to (IIf),

A-B-D	(IIa)
A-D	(IIb)
A-SO <sub>2</sub> -R <sup>3</sup>	(IIc)
A-SO <sub>3</sub> W	(II d)
A-COW	(IIe)
A-N <sub>3</sub>	(II f)

in which, independently of one another,

A is absent or is a C<sub>1</sub>-C<sub>8</sub>-alkylene radical and

B is a carbonyl group and

D is R<sup>2</sup>, OR<sup>2</sup>, NHR<sup>3</sup> or N(R<sup>3</sup>)<sub>2</sub>,

where R<sup>2</sup> is C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>6</sub>-C<sub>15</sub>-arylalkyl, C<sub>1</sub>-C<sub>8</sub>-haloalkyl or C<sub>5</sub>-C<sub>14</sub>-aryl and


R<sup>3</sup> is, in each case independently, C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>6</sub>-C<sub>15</sub>-arylalkyl or C<sub>6</sub>-C<sub>14</sub>-aryl or N(R<sup>3</sup>)<sub>2</sub> together is a cyclic amino radical, and

W is OH, NH<sub>2</sub>, or OM, where M may be an alkali metal ion, half an equivalent of an alkaline earth metal ion, an ammonium ion or an organic ammonium ion, and

~~R<sup>1</sup> is C<sub>4</sub>-C<sub>12</sub>-alkyl, C<sub>4</sub>-C<sub>12</sub>-haloalkyl, C<sub>6</sub>-C<sub>14</sub>-arylalkyl, C<sub>4</sub>-C<sub>40</sub>-aryl,~~

~~comprising reacting~~


~~stereoisomer mixtures of compounds of the formula (III)~~



~~in which~~

~~\*, Ar and R are as defined in the formula (I)~~

~~with compounds of the formula (IV)~~



in which


$R^1$  is as defined in the formula (I), and

$R^1$  is  $C_1$ - $C_{12}$ -alkyl,  $C_6$ - $C_{10}$ -aryl,  $C_6$ - $C_{11}$ -arylalkyl,  $C_2$ - $C_8$ -alkenyl or  $C_4$ - $C_{12}$ -haloalkyl

in the presence of polypeptides of the invention, which exert the biological activity of an using an anti-Kazlauskas lipase that is at least 80% identical to sequence SEQ ID NO 2.

14. (Cancelled)
15. (Cancelled)
16. (Currently Amended) Method according to Claim 13, characterized in that the beginning compound comprises a stereoisomer mixture[[s]] that is a ~~used are~~ racemic mixture[[s]] ~~of compounds of the formula (II).~~
17. (Currently Amended) Method according to Claim 13, characterized in that the beginning compound comprises a stereoisomer mixture where the reaction is stopped when conversion of the stereoisomer mixture employed at the start reaches 60 to 100% of the percentage of (S)-configured alcohol of the formula (II).
18. (Currently Amended) Method according to Claim 13, characterized in that the beginning compound comprises a stereoisomer mixture and where the method is carried out in the presence of a catalyst which racemizes the stereoisomer-enriched mixture[[s]] ~~of compounds of the formula (II).~~

19. (Previously Presented) Method according to Claim 18, characterized in that the catalysts used are those containing ruthenium complexes.
20. (Previously Presented) Method according to Claim 18, characterized in that the catalysts used are those containing
- a) ruthenium complexes of formula (IV),




in which

Ar is, in each case independently, phenyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted with C<sub>1</sub>-C<sub>4</sub>-alkyl,

and/or

- b) ruthenium complexes of the formula (V),



in which

Aren is a coordinated aromatic compound having from 6 to 12 ring carbons, which is optionally furthermore substituted with up to 6 radicals which are,

in each case independently of one another, selected from the group consisting of C<sub>1</sub>-C<sub>8</sub>-alkyl, benzyl and phenyl and

X is chlorine, bromine or iodine, preferably chlorine

and/or


c) ruthenium complexes of the formula (VI),



where

Aren and X are in each case as defined in formula (V) and (VII) is secondary or tertiary diamines, monoacylated or monosulphonated diamines, amino alcohols, amino acids and amino acid amides.

21. (Previously Presented) Method according to Claim 20, characterized in that in the formula (VI) (VII) represents compounds of the formula (VII),



in which


R<sup>5</sup> and R<sup>6</sup> are, in each case independently of one another, hydrogen, C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>4</sub>-C<sub>15</sub>-aryl or C<sub>5</sub>-C<sub>16</sub>-arylalkyl, or R<sup>5</sup> and R<sup>6</sup> together are a straight-chain or branched C<sub>3</sub>-C<sub>12</sub>-alkylene radical, and

R<sup>7</sup> is C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>1</sub>-C<sub>20</sub>-fluoroalkyl or C<sub>4</sub>-C<sub>15</sub>-aryl, and



A is SO<sub>2</sub> or CO.

22. (Previously Presented) Method according to Claim 18, characterized in that the catalyst is used in the presence of a base.
23. (Cancelled)
24. (Withdrawn) Method for preparing compounds of the formula (IIa)




in which

Ar and R are as defined in the formula (I) in Claim 13, and

\* indicates an (S)-stereogenic carbon atom in its absolute configuration,

comprising hydrolyzing

stereoisomer mixtures of the formula (Ia)



in which

Ar, R and R<sup>1</sup> are as defined in the formula (I), and

\* indicates an (S)-stereogenic carbon atom

in the presence of polypeptides according to Claims 10.

25. (Cancelled)

26. (Withdrawn) Method for preparing compounds of the formula (IIa)




in which

Ar and R are as defined in the formula (I) in Claim 13, and

\* indicates an (S)-stereogenic carbon atom in its absolute configuration,

comprising hydrolyzing

stereoisomer mixtures of the formula (Ia)



in which

Ar, R and R<sup>1</sup> are as defined in the formula (I), and

\* indicates an (S)-stereogenic carbon atom

in the presence of polypeptides according to Claim 11.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**